VOLITIONRX LTD (VNRX): Entry into a Material Definitive Agreement
VOLITIONRX LTD (VNRX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement . As previously reported, VolitionRx Limited (the “Company”) and Lind Global Asset Management XII LLC (“Lind”) entered into a Securities Purchase Agreement, dated May 15, 2025, as amended and restated on January 7, 2026 (the “
How this was made
The 30-second read
Why it matters
The waiver removes default triggers tied to ATM sales, allowing the company to raise additional capital beyond the $10 million cap.
Market read
Primary disclosure of a financing waiver that could affect share dilution and cash position of VNRX.
What to watch
Potential for the company to use proceeds for R&D milestones, which could improve long‑term valuation.
Background
SEC Form 8‑K filing discloses a material definitive agreement between VolitionRx Ltd. and Lind Global Asset Management.
Ticker impact
VolitionRx received a waiver from Lind allowing unlimited ATM share sales and removing default covenants.
Modest upside potential if market views additional financing positively; downside risk from dilution.
Waiver removes restrictions on ATM sales, a material corporate financing change for a micro‑cap.
Market effects
May signal increased financing activity in the biotech/clinical‑stage sector.
Limited to U.S. OTC market where VNRX trades.
Minimal global impact; primarily affects VNRX shareholders.
Counterpoint
The waiver could be seen as a sign of cash‑flow pressure, suggesting future dilution outweighs financing benefits.
Key entities
- companyVolitionRx Ltd.
Biotech company issuing senior secured convertible notes.
- investorLind Global Asset Management XII LLC
Holder of the convertible notes and warrant holder.
